Serotonin Receptor Agonists in the Treatment of Migraine: A Meta-Analysis Considering Possible Connection with Paresthesia.
作者信息
Katalinic Darko, Vcev Aleksandar, Smolic Martina, Aleric Ivan
机构信息
Faculty of Dental Medicine and Health and Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Osijek, Croatia.
出版信息
Ann Indian Acad Neurol. 2022 May-Jun;25(3):332-333. doi: 10.4103/aian.aian_266_22. Epub 2022 Jun 9.
Abstract
摘要
相似文献
1
Serotonin Receptor Agonists in the Treatment of Migraine: A Meta-Analysis Considering Possible Connection with Paresthesia.5-羟色胺受体激动剂治疗偏头痛：一项考虑与感觉异常可能关联的荟萃分析。
Ann Indian Acad Neurol. 2022 May-Jun;25(3):332-333. doi: 10.4103/aian.aian_266_22. Epub 2022 Jun 9.
2
Targeting to 5-HT1F receptor subtype for migraine treatment: lessons from the past, implications for the future.靶向5-HT1F受体亚型治疗偏头痛：过去的经验教训及对未来的启示。
Cent Nerv Syst Agents Med Chem. 2012 Dec;12(4):241-9. doi: 10.2174/187152412803760627.
3
Serotonin in migraine: theories, animal models and emerging therapies.偏头痛中的血清素：理论、动物模型及新兴疗法
Prog Drug Res. 1998;51:219-44. doi: 10.1007/978-3-0348-8845-5_6.
4
The Efficacy of Lasmiditan for the Treatment of Migraine: A Meta-Analysis of Randomized Controlled Studies.拉米替坦治疗偏头痛的疗效：随机对照研究的荟萃分析。
Clin Neuropharmacol. 2020 Nov/Dec;43(6):191-195. doi: 10.1097/WNF.0000000000000417.
5
Oral serotonin receptor agonists: a review of their cost effectiveness in migraine.口服5-羟色胺受体激动剂：偏头痛治疗中成本效益的综述
Pharmacoeconomics. 2005;23(3):259-74. doi: 10.2165/00019053-200523030-00006.
6
The Effect and Safety of 5-HT Receptor Agonist Lasmiditan on Migraine: A Systematic Review and Meta-Analysis.5-HT 受体激动剂拉米替坦治疗偏头痛的疗效和安全性：系统评价和荟萃分析。
Biomed Res Int. 2021 Oct 7;2021:6663591. doi: 10.1155/2021/6663591. eCollection 2021.
7
Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials.拉米替坦治疗成人偏头痛急性发作的系统评价和随机对照试验的荟萃分析。
CNS Drugs. 2020 Oct;34(10):1015-1024. doi: 10.1007/s40263-020-00753-1.
8
The Efficacy and Safety of DFN-15 for the Treatment of Migraine: A Meta-Analysis of Randomized Controlled Studies.DFN-15 治疗偏头痛的疗效和安全性：一项随机对照研究的荟萃分析。
Clin Neuropharmacol. 2020 Jul/Aug;43(4):107-111. doi: 10.1097/WNF.0000000000000401.
9
Frovatriptan succinate, a 5-HT1B/1D receptor agonist for migraine.琥珀酸夫罗曲普坦，一种用于偏头痛的5-HT1B/1D受体激动剂。
Int J Clin Pract. 2004 Jul;58(7):695-705. doi: 10.1111/j.1368-5031.2004.00218.x.
10
Novel Therapies in Acute Migraine Management: Small-Molecule Calcitonin Gene-Receptor Antagonists and Serotonin 1F Receptor Agonist.急性偏头痛管理中的新型治疗方法：小分子降钙素基因相关受体拮抗剂和 5-羟色胺 1F 受体激动剂。
Ann Pharmacother. 2021 Jun;55(6):745-759. doi: 10.1177/1060028020963574. Epub 2020 Sep 29.
引用本文的文献
1
CGRP Antagonism and Ketogenic Diet in the Treatment of Migraine.降钙素基因相关肽（CGRP）拮抗剂与生酮饮食治疗偏头痛。
Medicina (Kaunas). 2024 Jan 15;60(1):163. doi: 10.3390/medicina60010163.
本文引用的文献
1
Lasmiditan for the acute treatment of migraine.拉米地坦用于偏头痛的急性治疗。
Headache. 2020 Jun;60(6):1225-1226. doi: 10.1111/head.13798.
2
Migraine in adults with diabetes; is there an association? Results of a population-based study.成年糖尿病患者中的偏头痛；存在关联吗？一项基于人群研究的结果。
Diabetes Metab Syndr Obes. 2018 Jul 20;11:367-374. doi: 10.2147/DMSO.S170253. eCollection 2018.
3
Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential.5-羟色胺受体激动剂在偏头痛急性治疗中的应用：其治疗潜力综述
J Pain Res. 2018 Mar 8;11:515-526. doi: 10.2147/JPR.S132833. eCollection 2018.
4
Migraine in the triptan era: lessons from epidemiology, pathophysiology, and clinical science.曲坦类药物时代的偏头痛：来自流行病学、病理生理学及临床科学的经验教训
Headache. 2009 Feb;49 Suppl 1:S21-33. doi: 10.1111/j.1526-4610.2008.01336.x.
5
Can we develop neurally acting drugs for the treatment of migraine?我们能否研发出作用于神经的药物来治疗偏头痛？
Nat Rev Drug Discov. 2005 Sep;4(9):741-50. doi: 10.1038/nrd1822.
Zotero 插件